Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill takes aim at Hard-to-Treat KRAS cancers

NCT ID NCT06959615

Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests an experimental drug called JAB-23E73, taken as a pill, in people with advanced solid tumors that have a KRAS gene change. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors. About 334 participants will be enrolled across two phases: first to find the right dose, then to check for early signs of tumor response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JAB-23E73 (a pan-KRAS inhibitor pill)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have KRAS mutations, potentially shrinking tumors or slowing their growth.
What could go wrong
This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not work as hoped or could cause unexpected side effects. It is not yet proven to be safe or effective.
Why investors are watching

Jacobio Pharmaceuticals is testing JAB-23E73, a drug aimed at tumors with KRAS gene changes, in a phase I/IIa trial with 334 participants. For a small company, this early-stage readout matters because it will show whether the drug is safe and shows any sign of shrinking tumors, which could determine the drug's future and the company's direction.

If it works: If the trial shows the drug is safe and controls tumor growth, Jacobio could advance JAB-23E73 to later-stage testing, potentially making it a key asset for the company. A positive signal in a broad group of solid tumors could attract partnership interest from larger drugmakers.

If it fails: The trial could fail to show enough safety or antitumor activity, which would likely end the drug's development and hurt Jacobio's prospects. Early-phase cancer trials often fail, so a negative or unclear result is a real possibility.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 334 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer with evidence of KRAS gene alteration (including gene mutation and wild type amplification). 2. Able to provide an archived tumor tissue sample or fresh biopsy sample. 3. Life expectancy ≥3 months at the start of treatment. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. ≥1 measurable lesion per RECIST v1.1. 6. Adequate organ function. Exclusion Criteria: 1. Unable to swallow oral medications or with gastrointestinal dysfunction or gastrointestinal disease that significantly alters the absorption of medication. 2. Previous treatment with rat sarcoma (RAS) targeting agents. 3. Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases. 4. Impaired cardiovascular function or clinically significant cardiac disease. 5. Mean QT interval corrected using Fridericia's formula (QTcF) \>470 msec. 6. Females who are pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal neoplasm neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    32 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Anhui Provincial Cancer Hospital

    NOT_YET_RECRUITING

    Hefei, Anhui, 230001, China

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100032, China

  • Beijing Chest Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100032, China

  • Beijing Friendship Hospital, Capital Medical University

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100050, China

  • Fudan University Zhongshan Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian cancer Hospital

    NOT_YET_RECRUITING

    Fuzhou, Fujian, 350014, China

  • Guangxi Medical University Cancer Hospital

    RECRUITING

    Nanning, Guangxi, 530012, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Haerbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450003, China

  • Huashan Hospital Fudan University

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

  • Hunan Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, 200032, China

  • Jiangsu Cancer Hospital

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, 210009, China

  • Jiangsu Province Hospital

    RECRUITING

    Nanjing, Jiangsu, 210029, China

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

  • National Cancer Center/Cancer Hospital- Langfang Campus, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Langfang, Hebei, 065000, China

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100032, China

  • ShanXi Cancer Hospital

    RECRUITING

    Taiyuan, Shanxi, 650118, China

  • Shanghai Jiaotong University School of Medicine Ruijin Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510120, China

  • The First Affiliate of Soochow University

    NOT_YET_RECRUITING

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated hospital of Xi'an Jiaotong University

    NOT_YET_RECRUITING

    Xi’an, Shanxi, 710061, China

  • The First Affiliated hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, 450052, China

  • The First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110001, China

  • The Second Affiliate Hospital Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310009, China

  • Tianjin Medical University Cancer Institute&Hospital

    NOT_YET_RECRUITING

    Tianjin, Tianjin Municipality, 300211, China

  • Tongji Hospital

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430030, China

  • West China Hospital, Sichuan University

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610041, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310005, China

  • Zhejiang Provincial People's Hospital

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310014, China

  • Zhongnan Hospital of Wuhan University

    RECRUITING

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.